Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.23.1
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:        
Research and development $ 14,231 $ 8,686 $ 32,880 $ 23,912
General and administrative 2,911 2,068 8,872 6,632
Total operating expenses 17,142 10,754 41,752 30,544
Operating loss (17,142) (10,754) (41,752) (30,544)
Non-operating income (expense):        
Interest and other income, net 1,484   2,733 13
Loss from change in fair value of derivative liabilities (14) (12) (40) (8)
Employee retention credit       231
Interest expense   (442)   (1,329)
Total non-operating income (expense), net 1,470 (454) 2,693 (1,093)
Net loss (15,672) (11,208) (39,059) (31,637)
Other comprehensive loss:        
Net unrealized loss on available-for-sale marketable debt securities (132)   (132)  
Comprehensive loss $ (15,804) $ (11,208) $ (39,191) $ (31,637)
Net loss per common share - basic (in dollars per share) $ (0.30) $ (0.65) $ (0.76) $ (2.30)
Net loss per common share - diluted (in dollars per share) $ (0.30) $ (0.65) $ (0.76) $ (2.30)
Weighted average number of common shares outstanding - basic (in shares) 51,409 17,218 51,113 13,748
Weighted average number of common shares outstanding - diluted (in shares) 51,409 17,218 51,113 13,748